RecruitingNot ApplicableNCT07309471

Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD

Sponsor

University Hospital, Basel, Switzerland

Enrollment

24 participants

Start Date

Mar 6, 2026

Study Type

INTERVENTIONAL

Conditions

LSD Reaction

Summary

This study investigates DDH-LSD, a novel LSD-like compound expected to have a shorter duration of action than LSD. In healthy volunteers, pharmacokinetics, safety, and subjective effects, will be assessed and compare with LSD in a controlled cross-over study.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This Swiss study investigates DDH-LSD, a newly synthesized compound related to LSD (lysergic acid diethylamide), which is thought to have a shorter duration of psychedelic effects than LSD itself, potentially making it more practical for research or therapeutic applications. The study first identifies a safe and effective dose of DDH-LSD, then compares its effects to LSD and a placebo in a controlled, supervised setting to measure differences in subjective experience, duration, and physiological effects. Healthy adults aged 25–65 in Germany with no personal or close family history of psychotic or bipolar disorder, no chronic medical conditions, and no more than 20 prior uses of hallucinogens may be eligible. Participation involves attending multiple supervised sessions at a research facility where the substance is administered and closely monitored throughout the experience. This summary was generated by AI to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDDH-LSD

Single oral dose of DDH-LSD at the dose determined in Substudy 1. Participants are monitored for 13 hours for pharmacokinetics, subjective effects, autonomic responses, and safety parameters.

DRUGLSD

Single oral dose of 0.1 mg LSD. Participants are monitored for 13 hours for pharmacokinetics, subjective effects, autonomic responses, and safety parameters.

DRUGPlacebo

Single oral administration of placebo. Participants are monitored for 13 hours under identical conditions to control for expectancy and procedural effects.

Locations(1)

University Hospital Basel

Basel, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07309471